P

Procept Biorobotics Corp
NASDAQ:PRCT

Watchlist Manager
Procept Biorobotics Corp
NASDAQ:PRCT
Watchlist
Price: 30.38 USD -0.39%
Market Cap: 1.7B USD

Net Margin

-28.2%
Current
Improving
by 39.7%
vs 3-y average of -67.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-28.2%
=
Net Income
$-84.6m
/
Revenue
$299.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-28.2%
=
Net Income
$-84.6m
/
Revenue
$299.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Procept Biorobotics Corp
NASDAQ:PRCT
1.7B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
211.7B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
191.8B USD
Loading...
US
Stryker Corp
NYSE:SYK
139.1B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
130.5B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
124B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
59.1B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
49.5B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
57.2B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
49B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.6B USD
Loading...
No Stocks Found

Market Distribution

Lower than 77% of companies in the United States of America
Percentile
23nd
Based on 15 072 companies
23nd percentile
-28.2%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Procept Biorobotics Corp
Glance View

Market Cap
1.7B USD
Industry
Health Care

Procept Biorobotics Corp. is a pioneering force in the medical technology landscape, blending innovative engineering with clinical insights to address some of the most pressing challenges in urology. Founded with a vision to revolutionize surgical care, the company developed the AquaBeam Robotic System, an advanced medical platform that leverages robotic precision and real-time ultrasound imaging. This system is primarily employed in performing Aquablation therapy, a minimally invasive treatment designed to alleviate symptoms of benign prostatic hyperplasia (BPH). By integrating robotics and imaging, Procept offers a solution that enhances the accuracy of prostate tissue removal while minimizing risks and downtime for patients—a significant advancement over conventional methods. Revenue generation for Procept Biorobotics centers on the sales of their AquaBeam systems, along with consumables and service contracts that provide ongoing support and upgrades for their hospital and clinical partners. Recognizing the critical nature of procedure efficiency and safety, the company also invests in broadening the application of its technology and frequently seeks endorsements through clinical trials and studies to validate their innovations. By ensuring their cutting-edge solutions meet the stringent demands of healthcare professionals and patients alike, Procept maintains a competitive edge, fostering both adoption and trust within the healthcare community while steadily driving their growth and financial success.

PRCT Intrinsic Value
21.01 USD
Overvaluation 31%
Intrinsic Value
Price
P
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-28.2%
=
Net Income
$-84.6m
/
Revenue
$299.9m
What is Procept Biorobotics Corp's current Net Margin?

The current Net Margin for Procept Biorobotics Corp is -28.2%, which is above its 3-year median of -67.9%.

How has Net Margin changed over time?

Over the last 3 years, Procept Biorobotics Corp’s Net Margin has increased from -126% to -28.2%. During this period, it reached a low of -126% on Sep 30, 2022 and a high of -28.2% on Sep 30, 2025.

Back to Top